Nuvectis Pharma (NVCT) EBT (2021 - 2026)
Nuvectis Pharma (NVCT) posted EBT of -$7.1 million for Q1 2026, up 14.39% sequentially from -$8.3 million in Q4 2025, and little changed YoY from -$7.2 million in Q1 2025.
Nuvectis Pharma (NVCT) EBT (2021 - 2026) Analysis & Trends
Nuvectis Pharma has reported EBT for 6 years, with the latest figure at -$7.1 million in Q1 2026.
- Quarterly EBT changed 0.11% year-over-year to -$7.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$30.8 million (up 27.89% YoY) and the FY2025 annual result came in at -$27.5 million, up 28.69% from the prior year.
- EBT climbed to -$7.1 million in Q1 2026 per NVCT's latest filing, from -$8.3 million in the prior quarter.
- Over five years, EBT peaked at -$3.9 million in Q1 2022 and troughed at -$25.8 million in Q4 2024.
- A 5-year average of -$11.0 million and a median of -$8.3 million in 2025 frame the typical range for EBT.
- The sharpest annual moves came in 2023 and 2024: EBT tumbled 303.28% in 2023, then jumped 73.86% in 2024.
- Over 5 years, EBT stood at -$15.3 million in 2022, then tumbled by 38.27% to -$21.1 million in 2023, then dropped by 22.09% to -$25.8 million in 2024, then jumped by 67.62% to -$8.3 million in 2025, then rose by 14.39% to -$7.1 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$7.1 million, -$8.3 million, and -$8.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Nuvectis Pharma | 506.13 Mn | 506.13 Mn | - | -7.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.02 Mn |
| Mar 31, 2026 | -7.14 Mn |
| Dec 31, 2025 | -8.35 Mn |
| Sep 30, 2025 | -7.96 Mn |
| Jun 30, 2025 | -7.34 Mn |
| Mar 31, 2025 | -7.14 Mn |
| Dec 31, 2024 | -25.78 Mn |
| Sep 30, 2024 | -4.75 Mn |
| Jun 30, 2024 | -5.03 Mn |
| Mar 31, 2024 | -13.81 Mn |
| Dec 31, 2023 | -21.11 Mn |
| Sep 30, 2023 | -18.15 Mn |
| Jun 30, 2023 | -9.70 Mn |
| Mar 31, 2023 | -15.85 Mn |
| Dec 31, 2022 | -15.27 Mn |
| Sep 30, 2022 | -8.64 Mn |
| Jun 30, 2022 | -7.28 Mn |
| Mar 31, 2022 | -3.93 Mn |
| Dec 31, 2021 | -5.74 Mn |
| Sep 30, 2021 | -4.67 Mn |